<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Preparing patients for cardiac catheterization and possible coronary artery intervention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Preparing patients for cardiac catheterization and possible coronary artery intervention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Preparing patients for cardiac catheterization and possible coronary artery intervention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Poonam Velagapudi, MD, MS, FACC, FSCAI
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            J Dawn Abbott, MD, FACC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donald Cutlip, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1771271609">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac catheterization is an invasive procedure that is used for diagnostic and therapeutic purposes. This topic will discuss our approach to minimizing the risks of the procedure, increasing the likelihood of the procedure's goal(s), and optimizing the patient's experience. The content of this topic applies most specifically to patients for whom diagnostic coronary angiography and possible percutaneous coronary intervention are planned. Some content also applies to other cardiac procedures such as transcatheter valve replacement or cardiac electrophysiology.
        </p>
        <p>
         Related general topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1470.html" rel="external">
          "Complications of diagnostic cardiac catheterization"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">
          "Periprocedural complications of percutaneous coronary intervention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1569.html" rel="external">
          "Percutaneous coronary intervention with intracoronary stents: Overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H136765770">
         <span class="h1">
          PREPROCEDURE VISIT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once a decision has been made between the patient and the healthcare provider to proceed with cardiac catheterization, the procedure details should be discussed by the proceduralist or their representative. Patient confidence and compliance with practitioner instructions are strengthened when the procedure is explained adequately, including the benefits and risks, and in such a way as to give the patient sufficient time to ask questions or comment. During that discussion, the following potential patient concerns should be covered:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Why is the procedure being recommended?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are there reasonable alternatives to the procedure?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What is the practitioner's best guess as to the findings?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What will happen immediately before, during, and after the procedure?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Will the patient experience any pain?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Who will be in the room with the patient?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Will trainees be present?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What is the likely time of discharge?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When can the patient return to usual activity?
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2574463026">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following historical items should be carefully evaluated and well documented prior to the procedure:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of contrast allergy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of other drug allergies or adverse reactions (ie, sedation, anesthesia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of stroke, transient ischemic attack
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of symptoms of claudication or peripheral vascular interventions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of prior cardiac catheterization, including adverse events and findings
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of obstructive sleep apnea or difficult intubation
        </p>
        <p>
        </p>
        <p>
         The physical examination should focus on the following to determine a baseline:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Examination of the lungs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Examination of the heart.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Examination of arterial circulation, including the strength of the pulse at all locations and the absence or presence of bruits.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H547889573">
         <span class="h2">
          Informed consent
         </span>
         <span class="headingEndMark">
          —
         </span>
         Informed consent is necessary for patient protection and legal purposes. The procedure consent should be obtained well before elective procedures and as timely as possible in urgent procedures, such that patients have sufficient time to weigh the risks and benefits, understand alternative options, and discuss with family or other providers. It is important to discuss every procedure that may be performed. In general, these include diagnostic cardiac catheterization, coronary angiography, and possible percutaneous coronary intervention (PCI). In general, the consent document is usually signed just prior to the procedure.
        </p>
        <p>
         If PCI will be performed immediately following diagnostic catheterization, consent for PCI must be obtained prior to sedation and preferably at the time of consent for cardiac catheterization. If the anatomy is high risk, where the superiority of PCI as compared with other revascularization procedures (eg, coronary artery bypass graft surgery) is unclear or the risks are higher than an average PCI procedure, the precatheterization discussion may be insufficient [
         <a href="#rid1">
          1
         </a>
         ]. In these cases, it would be ideal to defer PCI procedure until after additional consultations and discussions. Emergency procedures such as ST-elevation myocardial infarction need prompt treatment, making true informed consent difficult [
         <a href="#rid2">
          2
         </a>
         ]. Every attempt must be made to discuss risks and benefits of the procedure and available alternate therapies with patients and family, and must balance the benefits of a good discussion with those of rapid intervention in these situations [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Patients with do-not-resuscitate status must be willing to revoke this status for at least 24 hours for the procedure [
         <a href="#rid4">
          4-8
         </a>
         ]. Possible exceptions include pericardiocentesis for end-stage malignancy or right-heart catheterization for end-stage heart failure.
        </p>
        <p class="headingAnchor" id="H1220093108">
         <span class="h2">
          Assess risks for bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients undergoing angiography and PCI procedures should be evaluated for risk of periprocedural bleeding since this is a risk factor for mortality due to the bleeding itself or cessation of antiplatelet or anticoagulant medications leading to ischemic events [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1573.html" rel="external">
          "Periprocedural bleeding in patients undergoing percutaneous coronary intervention"
         </a>
         .)
        </p>
        <p>
         Measures to mitigate risk include using radial rather than femoral access, ultrasound-guided access, and using smaller-diameter sheaths.
        </p>
        <p class="headingAnchor" id="H3307881705">
         <span class="h2">
          Baseline laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whenever feasible, laboratory tests for outpatient procedures may be done within 30 days of the procedure to look for any potential issues that require attention. Laboratory work may also be done on the morning of the procedure for patients who have had normal labs in the past.
        </p>
        <p>
         Laboratory tests should include hemoglobin/hematocrit, white blood cell count, platelet count, electrolytes (including sodium and potassium), blood urea nitrogen/creatinine, and an international normalized ratio for patients taking
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . Any test that is outside the normal range should be fully considered before the patient is asked to come to the hospital.
        </p>
        <p class="headingAnchor" id="H3987109100">
         <span class="h2">
          Electrocardiogram
         </span>
         <span class="headingEndMark">
          —
         </span>
         A baseline electrocardiogram (ECG) should be performed within 30 days of cardiac catheterization. This ECG will help operators delineate any new changes from ischemia or arrhythmia during or after the procedure.
        </p>
        <p class="headingAnchor" id="H3886504057">
         <span class="h2">
          Patient medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is important to review the patient's current medications. The following medications may need to be discontinued, have a dose alteration, or have a schedule change.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anticoagulants
         </strong>
         – The approach to the management of long-term anticoagulant therapy is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/101552.html" rel="external">
          "Periprocedural management of antithrombotic therapy in patients receiving long-term oral anticoagulation and undergoing percutaneous coronary intervention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/104830.html" rel="external">
          "Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants", section on 'Timing of anticoagulant interruption'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         – Metformin should be held for 48 hours before and after the procedure, particularly in patients with depressed left ventricular ejection fraction or chronic kidney disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Insulin dosing
         </strong>
         – Insulin dosing should be tailored to accommodate the patient's nil per os status.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Beta blockers
         </strong>
         – Beta blockers may be continued without interruption.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and diuretics
         </strong>
         – Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and diuretics may be continued up to the day of the procedure, held on the morning of the procedure, and resumed immediately postprocedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         <strong>
          and P2Y
         </strong>
         <strong>
          <sub>
           12
          </sub>
         </strong>
         <strong>
          inhibitors
         </strong>
         – Aspirin and P2Y
         <sub>
          12
         </sub>
         inhibitors may be continued without interruption.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sodium-glucose cotransporter-2 (SGLT2) inhibitors
         </strong>
         – Based on the risk of euglycemic diabetic ketoacidosis with SGLT2 inhibitors, they should be held 24 to 48 hours before major surgery, including cardiac catheterization procedures. These medications can generally be resumed once the patient is eating [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1963155181">
         <span class="h2">
          Transportation and diet
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should be driven to and from the facility in which the procedure will be performed, as they will not be able to drive themselves.
        </p>
        <p>
         Patients should be instructed to fast prior to a procedure for at least two hours after ingestion of clear liquids or at least six hours after ingestion of a meal, although some institutions require overnight nil per os status [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1924525516">
         <span class="h2">
          Prevention of contrast-related adverse outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Possible contrast-induced acute kidney injury and allergic reactions to contrast need to be considered in the preparation of all patients. All patients should be asked about a history of contrast allergy, and a preprocedural assessment of kidney function should be performed. These issues are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">
          "Prevention of contrast-associated acute kidney injury related to angiography", section on 'Prevention'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113083.html" rel="external">
          "Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography", section on 'Patients with past reactions to contrast'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2754619924">
         <span class="h2">
          Will trainees be involved?
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac catheterization procedures performed at universities and other teaching hospitals involve participation of trainees. The actual work performed by trainees may vary depending on their level of training, but supervision is mandatory.
        </p>
        <p class="headingAnchor" id="H2523045888">
         <span class="h1">
          PROCEDURAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2801713537">
         <span class="h2">
          Sedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A thorough assessment of whether the patient can tolerate sedation/anesthesia must be performed before the procedure. A patient's American Society of Anesthesiologists class and Mallampati Scale, which predict difficulty in intubation, should be documented.
        </p>
        <p>
         Moderate sedation and mild analgesia coupled with local anesthesia are crucial to minimize anxiety and sympathetic tone. A typical sedation protocol for the procedure might be a combination of 0.5 to 2 mg of
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         and 25 to 50 mcg of
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         , both by the intravenous (IV) route [
         <a href="#rid12">
          12
         </a>
         ]. Dosing must be carefully based on age, body weight, creatinine clearance, and comorbidities. Caution must be employed in elderly patients with history of respiratory insufficiency. All patients must receive local anesthesia with 1%
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         with no more than 0.5 to 1 mL at the site of puncture to avoid vasospasm from pain. Most patients can be managed successfully with midazolam and fentanyl. Intubated patients may require
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/139217.html" rel="external">
          "Procedural sedation in adults in the emergency department: Medication selection, dosing, and discharge criteria", section on 'Medications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3639200900">
         <span class="h2">
          Staffing requirements
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cardiac catheterization laboratory team consists of a credentialed physician (primary operator), possibly a physician trainee or physician assistant, a certified cardiovascular technologist, and a registered nurse (RN). The staffing requirements for a particular procedure depend on the type of case performed such as interventional versus diagnostic, elective versus emergency, and state and local hospital regulations. Typically, the cardiovascular technologists or physician assistant are at the tableside and are trained in sterile techniques, radiation safety, setting up equipment such as manifolds and injectors, and preparing catheters and wires for the procedure. The RN is involved with administering medications, continuous monitoring, and recording the patient's vital signs. All staff must have up-to-date advanced cardiac and basic life support certifications.
        </p>
        <p class="headingAnchor" id="H1193425254">
         <span class="h2">
          Vascular access
         </span>
         <span class="headingEndMark">
          —
         </span>
         The specifics of the performance of arterial access is beyond the scope of this topic. A few comments are made here. (See
         <a class="medical medical_review" href="/z/d/html/15192.html" rel="external">
          "Percutaneous arterial access techniques for diagnostic or interventional procedures"
         </a>
         .)
        </p>
        <p>
         For diagnostic coronary angiography and percutaneous coronary intervention (PCI), the radial and femoral arteries are the two most commonly chosen. The choice between the two is determined by the patient's anatomy, comorbid conditions, anticipated PCI technique, and physician practice. As access-site complications are the most common cause of procedure-related morbidity, it is of paramount importance to review prior cardiac catheterization reports when available to help understand the difficulties encountered to avoid potential complications. In addition, it is mandatory to check and document distal pulses in all four extremities immediately prior to the procedure.
        </p>
        <p>
         Femoral access was traditionally the preferred approach in the United States because of the large-bore diameter and ease of access. The transradial approach, however, has evolved as an alternative technique for both diagnostic- and interventional-related cardiac catheterizations [
         <a href="#rid13">
          13,14
         </a>
         ]. For urgent procedures, radial access is preferred given a lower risk of bleeding. If femoral access is absolutely necessary, then it is important to obtain access under fluoroscopic and ultrasound guidance.
        </p>
        <p class="headingAnchor" id="H709237059">
         <span class="h3">
          Femoral access
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although there is no absolute contraindication for femoral artery puncture, caution must be exercised in the following situations where use of the contralateral femoral artery, a radial artery, or an ultrasound-guided approach to the femoral artery must be considered: patients with absent or weak femoral artery pulse, femoral bruits, or iliofemoral bypass graft; prior vascular complications including pseudoaneurysm, femoral dissection, arteriovenous fistula, or ischemic limb; active groin infection; and history of iliofemoral or aortoiliac aneurysm [
         <a href="#rid15">
          15
         </a>
         ]. In addition, patients with calcified common femoral artery (seen on fluoroscopy), scarred groins from multiple prior procedures, and previous endovascular stents/grafts are at risk of vascular-closure device failure and would require manual compression to achieve hemostasis [
         <a href="#rid16">
          16
         </a>
         ]. Hence, it is of paramount importance to perform a femoral angiography to define the vascular system and identify the sheath location. Other scenarios in which femoral access should be avoided, if possible, include post-thrombolytic therapy, therapeutic oral anticoagulant, and bleeding diathesis.
        </p>
        <p>
         Common complications associated with femoral artery puncture include groin hematoma, retroperitoneal hematoma, arteriovenous fistulas, femoral pseudoaneurysm, and groin infection. (See
         <a class="medical medical_review" href="/z/d/html/1470.html" rel="external">
          "Complications of diagnostic cardiac catheterization", section on 'Local vascular complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15202.html" rel="external">
          "Access-related complications of percutaneous access for diagnostic or interventional procedures"
         </a>
         .)
        </p>
        <p>
         Large femoral hematomas and retroperitoneal bleeding are the most common causes of major bleeding with a reported incidence of 2.8 and 0.3 percent, respectively [
         <a href="#rid15">
          15
         </a>
         ]. Major risk factors include age &gt;75 years, severe renal impairment, female sex, postprocedure use of heparin, use of glycoprotein IIb/IIIa, and longer procedure time [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Femoral artery pseudoaneurysm is a common complication associated with low femoral arterial puncture. Manual compression with Doppler ultrasound guidance with or without thrombin injection are the accepted treatment strategies [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         In patients with prior femoral arterial access closed using a vascular closure device, the femoral artery cannot be reaccessed within 90 days if a collagen plug-based closure device is used, although reaccess 1 cm proximal to the prior access site can be considered. There are no restrictions to access groins closed using suture-based or nitinol-clip-based closure device [
         <a href="#rid15">
          15,17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1191345436">
         <span class="h3">
          Radial access
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to obtaining radial artery puncture, the Allen or Barbeau tests are conventionally used to assess dual circulation in the palmar arch. Despite no correlation, these tests are employed to potentially identify patients who may be at risk of hand ischemia in cases of radial artery occlusion:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         With the Allen test, the radial and the ulnar arteries are occluded by simultaneous manual compression until the palm blanches. Release of the ulnar artery should result in return of a pink hand within 8 to 10 seconds in a normal test. (See
         <a class="medical medical_review" href="/z/d/html/110008.html" rel="external">
          "Patient evaluation prior to placement of hemodialysis arteriovenous access", section on 'Allen test'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Barbeau test
         <em>
         </em>
         is a more objective assessment of the ulnar flow and is performed using pulse oximetry. A baseline arterial waveform is obtained when both arteries are open. The radial artery is manually occluded for two minutes and four responses (A, B, C, or D) are observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          A
         </strong>
         : No change in arterial waveform.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          B
         </strong>
         : Some dampening of the arterial waveform.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          C
         </strong>
         : Loss of arterial waveform but returns within two minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          D
         </strong>
         : Loss of waveform but takes longer than two minutes to return. Type D response is typically a contraindication for the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general, transradial access is avoided in the following scenarios:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absolute contraindication:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absence of bilateral radial artery pulses.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients receiving hemodialysis via arteriovenous fistula on the same side of the access site.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Relative contraindications:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Radial artery being considered for use in coronary artery bypass graft (CABG) surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Known upper extremity vascular disease including vascular anomalies, severe tortuosity, and vasospastic diseases.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence of right and left internal mammary artery graft may be less accessible.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Interventions requiring large-bore access.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1621412095">
         <span class="h2">
          Complications
         </span>
        </p>
        <p class="headingAnchor" id="H3131424534">
         <span class="h3">
          Contrast-related complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contrast-induced acute kidney injury is an important complication. Contrast media is excreted by the kidneys 30 to 60 minutes post-administration and a deterioration in kidney function can be detected as soon as few hours after the procedure. For patients with a baseline elevation of creatinine, we repeat the test within 12 to 48 hours.
        </p>
        <p>
         There is no absolutely safe limit of contrast dose, but a predictive value of contrast volume to creatinine clearance ratio &gt;3.7 was significantly associated with an early abnormal increase in serum creatinine after PCI [
         <a href="#rid18">
          18
         </a>
         ]. We recommend rechecking creatinine before discharge in patients with abnormal baseline values or when the dose of contrast used during the procedure exceeds the calculated maximum dose. Measures to minimize contrast volume during the procedure include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review of prior coronary angiograms and chest computer tomography if available, especially among patients with complex coronary disease or CABG.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding left ventriculography and aortography (if possible) by obtaining echocardiography prior to the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use automated injectors using in-line devices in the contrast tubing manifold compared with manual injection [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduce the number, volume, and frequency of contrast injections by making use of other anatomical radiopaque markers such as graft clips, calcification, and implantable cardiac devices.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use biplane angiography, especially in patients with chronic kidney disease [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of fractional flow reserve and intracoronary imaging can potentially reduce the amount of contrast injection by accurate lesion measurement [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Prevention of contrast-related allergy is discussed above (see
         <a class="local">
          'Prevention of contrast-related adverse outcomes'
         </a>
         above).
        </p>
        <p>
         Patients in the catheterization laboratory who develop circulatory collapse due to an anaphylactic reaction from contrast can be urgently treated with intravenous (IV)
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         (bolus followed by infusion) and IV fluids. The approach used to manage perioperative anaphylaxis is appropriate  (
         <a class="graphic graphic_table graphicRef107933" href="/z/d/graphic/107933.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ]. The management of anaphylaxis is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment", section on 'Pharmacologic treatments'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2811589796">
         <span class="h3">
          Catheter-induced coronary artery dissection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coronary artery dissection with a guide catheter during a diagnostic study is rare, with a reported incidence of 0.03 to 0.46 percent [
         <a href="#rid15">
          15
         </a>
         ]. The mechanism of the proximal dissection is due to mechanical trauma from catheter wedged into the intimal layer of the vessel and exacerbated by a jet of contrast from the abnormally located catheter. Catheter-induced dissection is more likely to occur with the right coronary artery when compared with the left coronary artery due to relative difference in the size of the ostia and the natural alignment of the catheter.
        </p>
        <p>
         Coronary dissection occurs more commonly with intervention during balloon dilation and can be classified into six types (type A: luminal haziness; type B: linear dissection; type C: extraluminal contrast staining; type D: spiral dissection; type E: dissection with reduced flow; type F: dissection with total occlusion). The reported incidence of dissection PCI is 30 to 50 percent [
         <a href="#rid15">
          15
         </a>
         ]. Stenting of the dissected vessel is the standard of care.
        </p>
        <p class="headingAnchor" id="H29460593">
         <span class="h3">
          Stroke
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of periprocedural stroke varies between 0.05 to 0.1 percent of diagnostic cardiac catheterizations and 0.18 to 0.44 percent of patients treated with PCI [
         <a href="#rid23">
          23
         </a>
         ]. Risk factors for periprocedural stroke include administration of thrombolytics prior to PCI, renal failure, urgent/emergent PCI, unplanned intraaortic balloon counterpulsation, advanced age, hypertension, and diabetes [
         <a href="#rid15">
          15,24
         </a>
         ]. Both in-hospital and one-year mortality among patients who suffer from cerebrovascular accident is high (up to 25 percent) [
         <a href="#rid24">
          24
         </a>
         ]. Stroke in the perioperative period warrants urgent brain imaging and neurologic consultation for consideration of intraarterial thrombolysis or mechanical thrombectomy. (See
         <a class="medical medical_review" href="/z/d/html/14083.html" rel="external">
          "Stroke after cardiac catheterization"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2076154202">
         <span class="h3">
          Allergic reactions to drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to contrast (see
         <a class="local">
          'Contrast-related complications'
         </a>
         above), patients may have immediate reactions to
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , nickel, latex,
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , and heparin in the catheterization laboratory. At times, it may not be immediately evident which of these is the culprit.
        </p>
        <p class="headingAnchor" id="H3121480675">
         <span class="h4">
          Aspirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to patients with a history of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         hypersensitivity is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/114687.html" rel="external">
          "Introduction of aspirin to patients with aspirin hypersensitivity requiring cardiovascular interventions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2980483181">
         <span class="h4">
          Nickel
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nickel allergy is a common cause of contact dermatitis. Coronary stents are made using 316L stainless steel, platinum-chromium, or cobalt-chromium alloy platforms, which include nickel (10 to 35 percent), chromium (18 to 20 percent), and molybdenum (2 to 10 percent) in varying amounts [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         In general, routine testing for nickel allergy and choosing the type of stent based on a history of nickel allergy are not recommended. Although early studies suggested an association between nickel allergy and restenosis in bare metal stents, prospective studies have not confirmed this. (See
         <a class="medical medical_review" href="/z/d/html/5556.html" rel="external">
          "Nickel hypersensitivity and coronary artery stents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H299424813">
         <span class="h4">
          Latex
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of latex allergy is estimated to be &lt;1 percent of the general population and up to 17 percent of healthcare workers [
         <a href="#rid26">
          26
         </a>
         ]. Direct contact with latex is not necessary, as latex can filter off the gloves and become an airborne pathogen in the closed environment of the cardiac catheterization laboratory. When a latex allergy is recognized, all procedures must be performed in a latex-free environment, which means no latex gloves or latex accessories should be in room. (See
         <a class="medical medical_review" href="/z/d/html/5543.html" rel="external">
          "Latex allergy: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5554.html" rel="external">
          "Latex allergy: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H280003782">
         <span class="h4">
          Lidocaine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically significant allergy to local
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         is rare. In such cases,
         <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">
          mepivacaine
         </a>
         1% or
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         0.25% should be used [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2084.html" rel="external">
          "Allergic reactions to local anesthetics", section on 'Types of allergic reactions to local anesthetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H117508519">
         <span class="h4">
          Heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common type of allergic reaction with heparin is a cell-mediated delayed type IV hypersensitivity reaction with clinical manifestations of skin necrosis, including pruritic erythematous plaques or maculae [
         <a href="#rid28">
          28-30
         </a>
         ]. Immediate type I allergic reactions (IgE-mediated) are rare [
         <a href="#rid29">
          29
         </a>
         ]. Due to its rarity, there are no standardized protocols to follow in the presence of any type of heparin allergy. Heparin-induced thrombocytopenia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3959275555">
         <span class="h2">
          Radiation safety basics
         </span>
         <span class="headingEndMark">
          —
         </span>
         All team members involved in the cardiac catheterization laboratory must receive training and education on radiation safety. Personal protective equipment includes lead aprons, shields, thyroid collars, caps, and lead glasses [
         <a href="#rid12">
          12,31
         </a>
         ]. Individual radiation exposure monitoring is of paramount importance, and all team members must be encouraged to always wear a radiation badge on the collar during the procedure. (See
         <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">
          "Radiation-related risks of imaging"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5325.html" rel="external">
          "Radiation dose and risk of malignancy from cardiovascular imaging"
         </a>
         .)
        </p>
        <p>
         The use of angulated views substantially increases radiation exposure. Left anterior oblique views produce greater exposure compared with right anterior oblique views. Typically, the default frame rate is 15 frames per second and decreases to 7.5 frames per second, and greater use of low-dose acquisition has been shown to have a marked reduction in total air kerma and air kerma rates [
         <a href="#rid32">
          32
         </a>
         ]. Furthermore, keeping the detector close to the patients, using lower-quality (lower frame-rate) fluoroscopy, and reducing the steepness of angulation are all measures to reduce operator radiation exposure [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1685632797">
         <span class="h1">
          POSTPROCEDURAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2602671907">
         <span class="h2">
          Hydration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adequate postprocedural hydration is the single most important measure to reduce contrast-induced kidney injury (see
         <a class="local">
          'Contrast-related complications'
         </a>
         above). Randomized controlled trials comparing isotonic bicarbonate with intravenous
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         showed no differences in the rates of renal outcomes [
         <a href="#rid33">
          33,34
         </a>
         ]. The POSEIDON trial was a randomized controlled trial including 396 patients that compared intensive pre- and postprocedural hydration using a strategy measurement of left ventricular end-diastolic pressure (LVEDP) versus usual care of normal saline 3 mL/kg for one hour before cardiac catheterization. The results demonstrated that contrast induced nephropathy occurred less frequently in the LVEDP group when compared with controls (6.7 versus 16.3 percent [relative risk 0.41, 95% CI 0.22-0.79]; p = 0.005) [
         <a href="#rid35">
          35
         </a>
         ]. Further intensive management with IV crystalloid in combination with forced diuresis using a fluid balance system demonstrated that elevation of urine output to &gt;150 mL/hour before and during the procedure reduced rates of contrast-induced kidney injury [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3947329564">
         <span class="h2">
          Time of discharge
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients can be discharged home the same day after uncomplicated diagnostic coronary angiography without high-risk findings such as significant left main or multivessel coronary artery disease involving proximal segments of major coronary arteries, and after uncomplicated planned or ad hoc percutaneous coronary intervention (PCI). Since sedation is administered for these procedures, patients should not be allowed to drive for at least 24 hours, and hence they need someone to drive them home. Other important factors include absence of access-site complications and absence of symptoms post-procedure before discharge. Patients with access-site or procedure-related complications, complex anatomy, and lack of support at home should be monitored overnight. A same-day discharge (SDD) checklist post-PCI may be used to make sure patients meet the required criteria before discharge [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Historically, patients who received PCI were monitored overnight for any complications. SDD after PCI has gained popularity in several countries, including the United States [
         <a href="#rid38">
          38-42
         </a>
         ]. The main advantages of SDD are improved patient satisfaction, shorter hospital length of stay, and reduced overall costs. Advances in stent implantation, vascular closure devices, and adjunctive pharmacotherapy are the primary reasons for greater adaptation of SDD programs. Given the widespread adaptation of the SDD programs, patient education with clear communication with the family about the potential risks after discharge is critical to ensure patient safety and prevention of legal liability.
        </p>
        <p>
         In 2021, the American College of Cardiology published an expert consensus document that details the conditions under which it is safe to discharge patients on the same day after PCI [
         <a href="#rid43">
          43
         </a>
         ]. We practice in a manner consistent with recommendations made in the document.
        </p>
        <p class="headingAnchor" id="H2886512366">
         <span class="h2">
          Post-procedure access site considerations
         </span>
        </p>
        <p class="headingAnchor" id="H3609518971">
         <span class="h3">
          Femoral artery access
         </span>
         <span class="headingEndMark">
          —
         </span>
         Manual compression, femoral compression systems, and vascular closure devices are the typical options in cases of femoral access. Although it is prudent to remove the femoral sheath as soon as possible, the timing of sheath removal is predominantly dictated by the patient's anticoagulation status. In patients who underwent a diagnostic study with minimal use of anticoagulation, sheaths can be removed immediately after the procedure. In patients who receive heparin, sheath removal can occur four to six hours after the infusion is stopped, when the activated clotting time (ACT) is approximately 150 to 180 seconds. For patients who receive
         <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">
          bivalirudin
         </a>
         , sheath removal can occur safely at two hours post-cessation of infusion in most patients. In patients receiving
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         , sheath removal can be safely performed 8 to 12 hours after the last dose [
         <a href="#rid12">
          12
         </a>
         ]. Checking ACT levels in patients who received bivalirudin or enoxaparin is not useful.
        </p>
        <p>
         In general, ambulation can be recommended after one to eight hours post-procedure and is typically dictated by the sheath size and success of vascular closure device. Patients who received manual compression can be ambulated after four to six hours, while those who received a vascular closure device may do so in one to four hours [
         <a href="#rid44">
          44-47
         </a>
         ]. Prior studies have demonstrated that vascular closure devices are associated with increased efficacy including reduced time to hemostasis, earlier ambulation, hospital discharge, and patient comfort. However, the safety of vascular closure devices has remained controversial, with studies showing a higher rate of vascular access site complications compared with manual compression [
         <a href="#rid48">
          48-50
         </a>
         ]. Nonetheless, despite a steep learning curve, vascular closure devices are considered safe in patients undergoing cardiac catheterization.
        </p>
        <p class="headingAnchor" id="H1570301456">
         <span class="h3">
          Radial artery access
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemostasis of the radial artery access site can be achieved by manual compression or mechanical wrist band compression device. All sheaths are removed at the end of the case. Given the superficial position and ease of compressibility, it is not necessary to check the ACT prior to sheath removal. A modified "reverse Allen's test" may be performed to check patency of the radial artery. A pulse oximetry test with arterial wave is seen after lowering the pressure in the compression device and simultaneous manual occlusion of the ulnar artery, hereby confirming patency of the radial artery [
         <a href="#rid51">
          51
         </a>
         ]. In our laboratory, a radial hemostatic device is left in place for approximately 30 minutes for diagnostic cardiac catheterization and approximately 90 minutes for PCI to achieve adequate hemostasis. Approximately 3 mL of air is deflated every 15 minutes until the band is completely deflated. In the absence of adequate hemostasis and return of bleeding, the air is reinjected, and the clock starts again. Patients should be able to be discharged after sedation wears off, within two hours after removal of the compression band. There are no ambulation restrictions, but patients are encouraged to avoid lifting weights or exercising their wrist for the next 24 hours.
        </p>
        <p class="headingAnchor" id="H3519566145">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meticulous preparation and execution of various important steps are essential prior to, during, and after cardiac catheterization procedures to ensure these procedures are performed safely and that patients have the best results with minimal complications. (See
         <a class="local">
          'Preprocedure visit'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Informed consent should be obtained prior to the procedure, and patients should be informed if trainees are going to be present in the procedure. Do-not-resuscitate status needs to be discussed and reversed for the procedure. (See
         <a class="local">
          'Informed consent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preprocedural steps include obtaining laboratory tests, correction of any electrolyte abnormalities, and assessing bleeding risk for appropriate access site selection. (See
         <a class="local">
          'Preprocedure visit'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient's medications must be reviewed, and clear instructions need to be provided regarding which medications should be held for the procedure. It is important to hold anticoagulation for a few days prior to the procedure to minimize the risk of bleeding. (See
         <a class="local">
          'Patient medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of contrast material is associated with risks of allergy and acute kidney injury. (See
         <a class="local">
          'Contrast-related complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discharge timing must be determined based on a multitude of patient- and procedure-related factors, with the goal of getting patients home safely. (See
         <a class="local">
          'Postprocedural considerations'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Blankenship JC, Mishkel GJ, Chambers CE, et al. Ad hoc coronary intervention. Catheter Cardiovasc Interv 2000; 49:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams BF, French JK, White HD, HERO-2 consent substudy investigators. Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study. Lancet 2003; 361:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bottinor W, Polkampally P, Jovin I. Adverse reactions to iodinated contrast media. Int J Angiol 2013; 22:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR Am J Roentgenol 1991; 157:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol 1991; 87:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witten DM, Hirsch FD, Hartman GW. Acute reactions to urographic contrast medium: incidence, clinical characteristics and relationship to history of hypersensitivity states. Am J Roentgenol Radium Ther Nucl Med 1973; 119:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urban P, Mehran R, Colleran R, et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation 2019; 140:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardia A, Wai M, Fontes ML. Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications. Curr Opin Anaesthesiol 2019; 32:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg RM, Berard LD, Cheng AYY, et al. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. Clin Ther 2016; 38:2654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naidu SS, Aronow HD, Box LC, et al. SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista; Affirmation of value by the Canadian Association of interventional cardiology-Association canadienne de cardiologie d'intervention). Catheter Cardiovasc Interv 2016; 88:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jhand A, Atti V, Gwon Y, et al. Meta-Analysis of Transradial vs Transfemoral Access for Percutaneous Coronary Intervention in Patients With ST Elevation Myocardial Infarction. Am J Cardiol 2021; 141:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao SV, Ou FS, Wang TY, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv 2008; 1:379.
          </a>
         </li>
         <li class="breakAll">
          Interventional cardiac catheterization handbook, 3rd ed, Kern MJ (Ed), Mosby, St. Louis 2011.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbetta I, van den Berg JC. Access and hemostasis: femoral and popliteal approaches and closure devices-why, what, when, and how? Semin Intervent Radiol 2014; 31:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore S, Bhatt DL. Femoral arterial access and closure. Circulation 2011; 124:e147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laskey WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 2007; 50:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minsinger KD, Kassis HM, Block CA, et al. Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy. Am J Cardiol 2014; 113:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane GC, Doyle BJ, Lerman A, et al. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol 2008; 51:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009; 360:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mariani J Jr, Guedes C, Soares P, et al. Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial. JACC Cardiovasc Interv 2014; 7:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werner N, Zahn R, Zeymer U. Stroke in patients undergoing coronary angiography and percutaneous coronary intervention: incidence, predictors, outcome and therapeutic options. Expert Rev Cardiovasc Ther 2012; 10:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs S, Stabile E, Kinnaird TD, et al. Stroke complicating percutaneous coronary interventions: incidence, predictors, and prognostic implications. Circulation 2002; 106:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romero-Brufau S, Best PJ, Holmes DR Jr, et al. Outcomes after coronary stent implantation in patients with metal allergy. Circ Cardiovasc Interv 2012; 5:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal S, Gawkrodger DJ. Latex allergy: a health care problem of epidemic proportions. Eur J Dermatol 2002; 12:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thind GS, Parida R, Gupta N. Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments. Ther Clin Risk Manag 2014; 10:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schindewolf M, Schwaner S, Wolter M, et al. Incidence and causes of heparin-induced skin lesions. CMAJ 2009; 181:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH. Heparin-induced skin lesions. Lancet 2012; 380:1867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schindewolf M, Kroll H, Ackermann H, et al. Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8:1486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirshfeld JW Jr, Ferrari VA, Bengel FM, et al. 2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging: Best Practices for Safety and Effectiveness: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018; 71:e283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal S, Parashar A, Ellis SG, et al. Measures to reduce radiation in a modern cardiac catheterization laboratory. Circ Cardiovasc Interv 2014; 7:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon R, Gordon P, Manoukian SV, et al. Randomized Trial of Bicarbonate or Saline Study for the Prevention of Contrast-Induced Nephropathy in Patients with CKD. Clin J Am Soc Nephrol 2015; 10:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008; 300:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 2014; 383:1814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon R. Forced diuresis with the RenalGuard system: impact on contrast induced acute kidney injury. J Cardiol 2014; 63:9.
          </a>
         </li>
         <li class="breakAll">
          Writing Committee, Rao SV, Vidovich MI, et al. 2021 ACC Expert Consensus Decision Pathway on Same-Day Discharge After Percutaneous Coronary Intervention: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020; S0735-1097(20)37778-0.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slagboom T, Kiemeneij F, Laarman GJ, van der Wieken R. Outpatient coronary angioplasty: feasible and safe. Catheter Cardiovasc Interv 2005; 64:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heyde GS, Koch KT, de Winter RJ, et al. Randomized trial comparing same-day discharge with overnight hospital stay after percutaneous coronary intervention: results of the Elective PCI in Outpatient Study (EPOS). Circulation 2007; 115:2299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shroff A, Kupfer J, Gilchrist IC, et al. Same-Day Discharge After Percutaneous Coronary Intervention: Current Perspectives and Strategies for Implementation. JAMA Cardiol 2016; 1:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao SV, Kaltenbach LA, Weintraub WS, et al. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. JAMA 2011; 306:1461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amin AP, Patterson M, House JA, et al. Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States. JACC Cardiovasc Interv 2017; 10:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Writing Committee, Rao SV, Vidovich MI, et al. 2021 ACC Expert Consensus Decision Pathway on Same-Day Discharge After Percutaneous Coronary Intervention: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021; 77:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Logemann T, Luetmer P, Kaliebe J, et al. Two versus six hours of bed rest following left-sided cardiac catheterization and a meta-analysis of early ambulation trials. Am J Cardiol 1999; 84:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steffenino G, Dellavalle A, Ribichini F, et al. Ambulation three hours after elective cardiac catheterisation through the femoral artery. Heart 1996; 75:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doyle BJ, Konz BA, Lennon RJ, et al. Ambulation 1 hour after diagnostic cardiac catheterization: a prospective study of 1009 procedures. Mayo Clin Proc 2006; 81:1537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulz-Schüpke S, Helde S, Gewalt S, et al. Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial. JAMA 2014; 312:1981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koreny M, Riedmüller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA 2004; 291:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biancari F, D'Andrea V, Di Marco C, et al. Meta-analysis of randomized trials on the efficacy of vascular closure devices after diagnostic angiography and angioplasty. Am Heart J 2010; 159:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nikolsky E, Mehran R, Halkin A, et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol 2004; 44:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pancholy S, Coppola J, Patel T, Roke-Thomas M. Prevention of radial artery occlusion-patent hemostasis evaluation trial (PROPHET study): a randomized comparison of traditional versus patency documented hemostasis after transradial catheterization. Catheter Cardiovasc Interv 2008; 72:335.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 130577 Version 12.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10642758" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Ad hoc coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12648970" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22064601" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24436602" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Adverse reactions to iodinated contrast media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1950858" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2343107" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2013681" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The prevention of immediate generalized reactions to radiocontrast media in high-risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4765627" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Acute reactions to urographic contrast medium: incidence, clinical characteristics and relationship to history of hypersensitivity states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31116032" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30531609" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28003053" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27137680" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista; Affirmation of value by the Canadian Association of interventional cardiology-Association canadienne de cardiologie d'intervention).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33220324" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Meta-Analysis of Transradial vs Transfemoral Access for Percutaneous Coronary Intervention in Patients With ST Elevation Myocardial Infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19463333" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19463333" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25435661" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Access and hemostasis: femoral and popliteal approaches and closure devices-why, what, when, and how?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21810667" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Femoral arterial access and closure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17692741" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24188890" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174044" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19144937" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25326742" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23190068" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Stroke in patients undergoing coronary angiography and percutaneous coronary intervention: incidence, predictors, outcome and therapeutic options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093775" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Stroke complicating percutaneous coronary interventions: incidence, predictors, and prognostic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22456027" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Outcomes after coronary stent implantation in patients with metal allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12095872" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Latex allergy: a health care problem of epidemic proportions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25364258" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19786468" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Incidence and causes of heparin-induced skin lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22642893" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Heparin-induced skin lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20128858" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29729877" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : 2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging: Best Practices for Safety and Effectiveness: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25097198" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Measures to reduce radiation in a modern cardiac catheterization laboratory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26185263" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Randomized Trial of Bicarbonate or Saline Study for the Prevention of Contrast-Induced Nephropathy in Patients with CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18768415" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24856027" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24239195" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Forced diuresis with the RenalGuard system: impact on contrast induced acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24239195" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Forced diuresis with the RenalGuard system: impact on contrast induced acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15789393" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Outpatient coronary angioplasty: feasible and safe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17420341" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Randomized trial comparing same-day discharge with overnight hospital stay after percutaneous coronary intervention: results of the Elective PCI in Outpatient Study (EPOS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27437896" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Same-Day Discharge After Percutaneous Coronary Intervention: Current Perspectives and Strategies for Implementation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21972308" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28231901" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33423859" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : 2021 ACC Expert Consensus Decision Pathway on Same-Day Discharge After Percutaneous Coronary Intervention: A Report of the American College of Cardiology Solution Set Oversight Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10468098" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Two versus six hours of bed rest following left-sided cardiac catheterization and a meta-analysis of early ambulation trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8665340" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Ambulation three hours after elective cardiac catheterisation through the femoral artery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17165631" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Ambulation 1 hour after diagnostic cardiac catheterization: a prospective study of 1009 procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25399273" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14734598" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20362708" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Meta-analysis of randomized trials on the efficacy of vascular closure devices after diagnostic angiography and angioplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364320" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18726956" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prevention of radial artery occlusion-patent hemostasis evaluation trial (PROPHET study): a randomized comparison of traditional versus patency documented hemostasis after transradial catheterization.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
